Cambridge: AstraZeneca has announced $3.5 billion of capital investment in the United States focused on expanding the Company ...

The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

CAMBRIDGE, Britain (AP) — CAMBRIDGE, Britain (AP) — Astrazeneca PLC (AZN) on Tuesday reported third-quarter earnings of $1.43 billion. On a per-share basis, the Cambridge, Britain-based company said ...

AstraZeneca, headquartered in Cambridge UK but globally influential, is investing $3.5 billion in the United States to expand ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

The decision to pause its investment in Britain came as AstraZeneca announced plans to spend $3.5bn (£2.7bn) expanding its US ...

Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...

AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...

CAMBRIDGE, England, November 12, 2024--(BUSINESS WIRE)--AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

AstraZeneca (AZN) said it plans to spend $3.5B to expanding its research and manufacturing capabilities in the United States ...